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Abstract
Purpose—Current information regarding pregnancy-associated cardiomyopathy among women 
treated for childhood cancer is insufficient to appropriately guide counseling and patient 
management. This study aims to characterize its prevalence within a large cohort of females 
exposed to cardiotoxic therapy.
Methods—Retrospective cohort study of female cancer survivors treated at St. Jude Children’s 
Research Hospital between 1963 and 2006, at least 5 years from diagnosis, ≥ 13 years old at last 
follow-up, and with at least one successful pregnancy. Pregnancy-associated cardiomyopathy was 
defined as shortening fraction < 28% or ejection fraction < 50% or treatment for cardiomyopathy 
during or up to 5 months after completion of pregnancy.
Results—Among 847 female cancer survivors with 1554 completed pregnancies only 3 (0.3%) 
developed pregnancy-associated cardiomyopathy, 40 developed non-pregnancy-associated 
cardiomyopathy either 5 months post-partum (n=14), or prior to pregnancy (n=26). Among those 
with cardiomyopathy prior to pregnancy (n=26), cardiac function deteriorated during pregnancy in 
8 patients (3 patients with normalization of cardiac function prior to pregnancy, 3 with persistently 
abnormal cardiac function, and 2 for whom resolution of cardiomyopathy was unknown prior to 
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pregnancy). Patients that developed cardiomyopathy recevied a higher median dose of 
anthracyclines compared to those that did not (321 mg/m2 versus 164 mg/m2; p< 0.01).
Conclusions—Pregnancy-associated cardiomyopathy in childhood cancer survivors is rare.
Implications for cancer survivors—Most female childhood cancer survivors will have no 
cardiac complications during or after childbirth, however those with a history of cardiotoxic 
therapies should be followed carefully during pregnancy particularly those with a history of 
anthracycline exposures and if they had documented previous or current subclinical or 
symptomatic cardiomyopathy. Female childhood cancer survivors with a history of cardiotoxic 
therapies should be followed carefully during pregnancy particularly those with a history of 
anthracycline exposures and if they had documented previous or current subclinical or 
symptomatic cardiomyopathy.
Keywords
pregnancy associated cardiomyopathy; cardiac toxicity; childhood cancer survivor; cardiotoxic 
therapies
INTRODUCTION
The survival rate for children diagnosed with cancer has increased significantly over the last 
50 years and with it an awareness of the long-term effects of therapy. Cardiac sequelae of 
radiation therapy and anthracycline exposure have been well documented and manifest most 
commonly as left ventricular dilatation with reduced cardiac output or dilated 
cardiomyopathy, but also include ischemic heart disease, heart valve dysfunction, and/or 
conduction disorders [1–9]. Survivors at highest risk are those exposed to both radiation 
therapy that includes the heart and anthracyclines [2, 6]. Radiation dose and field and the 
cumulative anthracycline dose are the most important risk factors, but the incidence and 
severity of cardiac damage may also be influenced by host (e.g., age at treatment, gender, 
race) and lifestyle factors (tobacco and drug use, diet, weight management). [2, 6, 10–14]. 
Subclinical cardiac toxicity following anthracycline therapy has also been reported, but its 
natural history and rate of progression to clinical heart failure is unknown [15]. Physiologic 
stresses, such as pregnancy, have been hypothesized to precipitate cardiac decompensation 
among survivors exposed to cardiotoxic therapies who do not have clinical evidence of 
cardiomyopathy. However, limited data support this claim. Within the general population, 
peripartum cardiomyopathy, defined as cardiac dysfunction with no identifiable cause 
during the last month of pregnancy or up to five months postpartum, is rare [16]. Among 
cancer survivors, pregnancy-associated cardiomyopathy has been anecdotally linked to 
anthracycline exposure, but formal assessment of left ventricular systolic function before 
pregnancy was not documented in these reports [17–21]. In small case series of childhood 
cancer survivors with pre-pregnancy assessment of cardiac function, pregnancy-associated 
cardiomyopathy did not develop in women with normal left ventricular systolic function [18, 
19]. In general, current information regarding pregnancy-associated cardiomyopathy among 
women treated for childhood cancer is insufficient to appropriately guide counseling and 
patient management. This study aims to address this knowledge gap by characterizing the 
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prevalence of and risk factors for pregnancy-associated cardiomyopathy within a large 
cohort of female childhood cancer survivors exposed to cardiotoxic therapy.
PATIENTS AND METHODS
Patient Selection and Data
Patients included in the study were female cancer survivors treated at St. Jude Children’s 
Research Hospital (SJCRH) between May 16, 1963 and May 25, 2006, who were at least 5 
years from diagnosis, ≥ 13 years old at last follow-up, and known to have completed at least 
one pregnancy through delivery. Participants were either patients of the After Completion of 
Therapy Clinic (ACT Clinic) or enrolled in the St Jude Lifetime Cohort (SJLIFE) Study 
[22]. These patients are no longer undergoing therapy for their original cancer diagnosis but 
have continuous follow-up to ascertain health outcomes. ACT Clinic (started in early 
1990’s) patients are evaluated yearly for at least 10 years after initial cancer diagnosis or 
until they reach 18 years of age. ACT Clinic patients that have cardiotoxic exposures are 
screened for cardiac disease as recommended by the Children’s Oncology Group Long-Term 
Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers 
(www.survivorshipguidelines.org) [23]. After ‘graduation’ from the clinic, they are sent 
annual questionnaires inquiring about their health status and new health events as well as 
pregnancies and pregnancy related complications including medications. Those in the 
SJLIFE Study are ≥ 18 years of age and ≥ 10 years from their cancer diagnosis. Eligibility 
and recruitment details for this study have been previously published [29]. SJLIFE 
participants also undergo risk-based health evaluations as recommended by the Children’s 
Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, 
and Young Adult Cancers (www.survivorshipguidelines.org) [23] including 
echocardiograms (every year to every 5 years based on risk) if treated with cardiotoxic 
therapies.
Information extracted from the survivorship database for this analysis included: diagnosis, 
age at diagnosis, self-identified race, number and dates of pregnancies, previous 
cyclophosphamide, ifosfamide, and anthracycline exposures including cumulative doses, 
chest radiation treatment fields, and date of last follow-up. Anthracycline equivalent 
exposure was calculated by multiplying the cumulative doses of doxorubicin × 1, 
daunorubicin × 0.833, epirubicin × 0.67, idarubicin × 5 and mitoxantrone × 4 [24, 25]. 
Radiation exposure was considered if the field included the heart. Records were reviewed 
for patients who had a history of cardiomyopathy to ascertain a possible association with 
pregnancy. The results of previous echocardiograms and pregnancy history (self reported) 
were reviewed. Patients were not followed by our facility during pregnancies and patients 
were not specifically seen for prenatal or postnatal visits. Echocardiograms were obtained by 
other facilities by the attending physician following them. Medical records (clinic notes, 
echocardiogram and electrocardiogram reports) were obtained to validate reports of 
cardiovascular disease diagnosed at other facilities. The study was approved by the 
Institutional Review Board.
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Definition of nonpregnancy associated cardiomyopathy and pregnancy associated 
cardiomyopathy
Nonpregnancy associated cardiomyopathy was defined as shortening fraction (SF) < 28% or 
ejection fraction (EF) < 50% on echocardiogram or treatment for cardiomyopathy that did 
not occur during pregnancy or within 5 months of delivery. The cardiomyopathy was 
considered subclinical if it was asymptomatic and did not require any treatment.
Pregnancy-associated cardiomyopathy was defined as SF < 28% or EF < 50% diagnosed 
during or within 5 months of delivery or treatment for cardiomyopathy during this interval 
in a patient with no previous diagnosis of cardiomyopathy.[16, 26]
RESULTS
Patient Characteristics
There were a total of 2737 females who survived five years and were at least age 13 and 
who were treated during the time period specified and were alive at the time of our analysis, 
while 219 met the eligibility criteria but were expired at the time of our analysis. For this 
study the patient cohort comprised 847 (31%) female survivors of childhood cancer with 
1554 documented completed pregnancies (median=2, range: 1–5 pregnancies). No known 
therapeutic abortions due to cardiomyopathy were reported. Median age at cancer diagnosis 
was 10.3 years (range, 1 month – 22.6 years; Table 1). Most patients (83%) were white. 
Over half of the cohort had been treated for leukemia (38%) or lymphoma (23%). 
Cardiotoxic treatment exposures included only anthracycline agents in 237 (28%), only 
radiation therapy with fields involving the heart in 140 (17%), both modalities in 248 
patients (29%) and neither in 222 patients (27%). Among 484 women treated with 
anthracyclines, 376 (44%) received a cumulative dose < 300 mg/m2, 72 (9%) received ≥ 300 
and < 400 mg/m2, 26 (3%) received ≥ 400 and < 500 mg/ m2, and 9 (1%) received ≥ 500 
mg/ m2 (median 200 mg/m2, range: 39–721 mg/m2), and one patients received an unknown 
anthracycline dose. In addition, 459 (54%) and 54 (6%) of the survivors received 
cyclophosphamide (median 7,313 mg/m2, range: 300–38,576 mg/m2) and ifosfamide 
(median 39,728 mg/m2 range: 6,000–79,606 mg/m2), respectively. Median follow-up time 
from diagnosis was 26.5 years (range: 6–48.4 years). Most patients were seen or contacted 
within the last (61%) or 2 years (90%).
Overall prevalence of cardiomyopathy
We identified 43 women (5%) with development of cardiomyopathy at a median time of 10 
years (2 weeks to 37 years) from cancer diagnosis. Forty had non-pregnancy associated 
cardiomyopathy (26 before pregnancy and 14 > five months postpartum) and 3 had 
pregnancy associated cardiomyopathy (Figure 1). Cardiotoxic exposures included 
anthracyclines in 29 (67%), radiation fields involving the heart in 4 (9%), both cardiotoxic 
modalities in 9 (21%), and neither exposure in 1 patient. Prevalence of cardiomyopathy in 
patients that had both radiation and anthracycline exposure was 3.6% (9 of 248 patients). 
Prevalence of cardiomyopathy in patients that received anthracycline alone was 12% (29 of 
237). Additionally, 33 (77%) of those with cardiomyopathy received cyclophosphamide and 
6 (14%) ifosfamide. Current age, age at diagnosis, and race did not differ among women 
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who did and did not develop cardiomyopathy (Table 1). Those diagnosed with 
cardiomyopathy had a higher anthracycline exposure compared to those without 
cardiomyopathy (median dose 321 mg/m2 vs 164 mg/m2, p< 0.01; t-test).
Patients with non-pregnancy-associated cardiomyopathy
A total of 40 (4.7% of the whole cohort) women developed non-pregnancy-associated 
cardiomyopathy (Figure 1 and Table 2). There were 14 of these women who developed a 
cardiomyopathy more than five months post-partum (subclinical in 1; 13 requiring 
medication; median time to CMP diagnosis, 24 years after cancer treatment, range, 9–36 
years; median time to CMP diagnosis after last pregnancy was 5.5 years, range, 1–26 years). 
Twenty-six of the 40 women were diagnosed with cardiac dysfunction prior to becoming 
pregnant (subclinical in 16; 10 on medication). Among those diagnosed prior to becoming 
pregnant, 16 had documented normalization of function prior to becoming pregnant, 8 had 
persistent cardiomyopathy, and for 2 patients follow-up of previously diagnosed 
cardiomyopathy was unavailable prior to becoming pregnant (both of these women had 
further deterioration of cardiac function during pregnancy). Among the 16 women who had 
normal function prior to becoming pregnant, 3 had recurrent deterioration of function during 
their pregnancies. Among the 8 women with persistent cardiomyopathy, 3 deteriorated 
during pregnancy but 5 remained stable (Table 3 and Supplemental Table). Again after 
detailed examination of past records for these patients, no therapeutic abortions secondary to 
cardiomyopathy were reported
In addition we wanted to explore how many of our nonpregnancy associated patients had 
scheduled echocardiogram prior to their pregnancies. Of the 40 women diagnosed with 
nonpregnancy-associated cardiomyopathy, 34 patients (85%) had documentation of their 
cardiac function by echocardiogram prior to their first pregnancy (26 (81%) patients with 
normal echocardiogram, 8 patients with subclinical cardiomyopathy). Twenty-six patients of 
this group had a second pregnancy with 13 patients (50%) having echocardiograms prior to 
second pregnancy (8 patients (66%) with normal heart function and 5 patients with 
subclinical cardiomyopathy). Six of 9 patients (67%) with third pregnancy in this group had 
cardiac function documented by echocardiogram with 4 of these patients (83%) with 
documented normal echocardiogram. Only 4 patients in this group had a fourth pregnancy 
and only one patient had an echocardiogram documented prior to the fourth pregnancy. 
Median time of echocardiogram prior to each pregnancy was 1.3 years (range 0.25 to 16 
years).
Patients with pregnancy-associated cardiomyopathy
Only 3 women (0.4% of the cohort) with no prior history of cardiomyopathy developed 
cardiomyopathy during pregnancy (Tables 2 and 4). Patient 1 is described in a previous case 
report by Davis et al [20]. The patient received doxorubicin (523 mg/m2) for osteosarcoma 
diagnosed at 6 years of age. Serial echocardiograms during and after therapy documented 
normal cardiac function with her last serial echocardiogram performed 5 years after therapy. 
At 13 years of age she delivered her first baby via Cesarean section that was complicated by 
significant blood loss requiring large volume fluid resuscitation. Within hours of delivery 
she developed pulmonary edema and her echocardiogram showed a shortening fraction of 
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9% with global hypokinesia. Her cardiac function normalized on inotropic and diuretic 
therapy. There have been no other recorded pregnancies for this patient.
Patient 2 received doxorubicin (cumulative dose 385 mg/m2) for Ewing sarcoma diagnosed 
at 8 years of age. Serial echocardiograms up to 10 years after completion of therapy 
confirmed normal left ventricular systolic function. At 31 years of age, she developed 
cardiomyopathy (ejection fraction 35% to 40% with global hypokinesia) following delivery 
of her first child by Cesarean section. Her left ventricular function subsequently normalized 
on a beta-blocker and diuretics, and she remains on a beta blocker. This patient has had no 
other recorded pregnancies.
Patient 3 received daunorubicin (cumulative dose 84 mg/m2) for acute lymphoblastic 
leukemia diagnosed at 7 years of age. Echocardiogram performed 8 years after therapy 
showed normal cardiac function. At age 19, she developed cardiomyopathy (ejection 
fraction 40% to 45% with mild global hypokinesia) in the 24th week of her first pregnancy. 
She was treated with beta-blocker therapy for the rest of her pregnancy and had no 
complications with delivery. Her left ventricular function subsequently normalized 6 months 
after delivery at which time medication was discontinued. There have been no other 
pregnancies recorded for this patient.
COMMENT
In a large and well-characterized cohort of female childhood cancer survivors with 
prolonged follow-up, we found a low incidence of clinically significant pregnancy-
associated cardiomyopathy. As has been previously described our patients are very 
committed and willing to be in continuos communication providing information about life 
changing events such as pregnancies and cardiac events, with less than 10% considered lost 
to follow up. [22] While women exposed to cardiotoxic cancer regimens were at risk for 
developing cardiomyopathy later in life, only 3 (0.2% of all pregnancies) without any known 
prior decrease in cardiac function had decompensation during their pregnancies. However, 
among the cancer survivors with a diagnosis of cardiac dysfunction prior to becoming 
pregnant, 8 of 26 either had recurrent cardiomyopathy (n=3) or further decrease in function 
(n=5) during pregnancy, suggesting an increased peripartum risk for survivors with previous 
evidence of cardiac toxicity [16]. The current recommended mode of delivery in women 
with pre-existing dilated cardiomyopathies is vaginal if there are no obstetric 
contraindications. Vaginal deliveries are associated with less blood loss and are overall 
found to be more hemodynamically stable causing less stress to the cardiocirculatory 
system. [27]
While low, the incidence of peripartum cardiomyopathy in our cohort is nearly 10-fold 
higher than what has been reported in the general U.S. population but comparable to other 
reports among childhood cancer survivors. The National Institutes of Health workshop [16] 
on peripartum cardiomyopathy reported an incidence of 1 in 3000 to 4000 (0.03%) live 
births in the general population compared to the 3 in 1514 (0.2%) births (excluding the 40 
births complicated by non-pregnancy associated cardiomyopathy) in this cohort of cancer 
survivors. However, in a study by Van Dalen et al. [18], none of 53 women previously 
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exposed to anthracycline therapies who delivered one or more children developed 
pregnancy-associated cardiomyopathy. Patients in the Van Dalen study were diagnosed by 
symptoms without echocardiograms leading to possible underreporting of subclinical 
cardiomyopathy. Our study identified patients with subclinical cardiomyopathy because of 
frequent echocardiograms performed as part of surveillance before and after therapy, and 
confirms the low incidence of pregnancy associated cardiomyopathy in a much larger 
cohort. As in our study, Van Dalen et al. considered other therapies including radiation, 
ifosfamide, and cyclophosphamide, but the risk for cardiomyopathy related to these 
therapies could not be assessed because none of the exposed patients developed 
symptomatic pregnancy-associated cardiomyopathy. Bar et al. [19] conducted a longitudinal 
study of 37 women previously treated with anthracyclines using screening echocardiograms 
before, during, and after therapy as well as before, during, and after pregnancy. Women with 
normal function (SF ≥ 30%) prior to pregnancy remained stable, but those (8 of 37; 22%) 
with a decreased shortening fraction (SF < 30%) prior to pregnancy had further 
decompensation during pregnancy (19% SF decrease post pregnancy). Our study supports 
these findings, suggesting an association of pre-pregnancy subclinical impairment of cardiac 
function with worsening subclinical cardiomyopathy during pregnancy.
Compared to previous reports [12, 18, 19], our study provides more robust data to reassure 
survivors and health care providers of the low risk of peripartum cardiomyopathy among 
female childhood cancer survivors, even among women treated with relatively “high-risk” 
cardiotoxic exposures, particularly those who maintain normal cardiac function during 
follow up. In our cohort, two of three women who developed pregnancy-associated 
cardiomyopathy received total anthracycline doses ≥ 250 mg/m2 as well as other concurrent 
cardiotoxic drugs (including cyclophosphamide). Cyclophosphamide has been associated 
with acute myocarditis but has not been found to cause chronic cardiomyopathy [13, 28]. 
Average total anthracycline doses reported in previous studies were > 240 mg/m2 [12, 17, 
18, 20]. Higher doses of anthracycline (≥ 250 mg/m2) exposure were also administered to 
65% of the non-pregnancy-associated cardiomyopathy patients. Interestingly, none of our 
patients with pregnancy-associated cardiomyopathy had radiation treatment fields involving 
the heart. There was no apparent association of increased risk of cardiomyopathy with 
exposure to both radiation and anthracycline (3%) compared to anthracycline alone (12%). It 
appears from this study that, while a previous history of cardiomyopathy (including 
subclinical cardiomyopathy) does not predict cardiomyopathy during pregnancy, there may 
be an increased risk of worsening heart function even in patients whose heart function had 
normalized prior to pregnancy as 3 out of 16 patients (19%) had recurrent cardiomyopathy 
during pregnancy. Furthermore, our data supports that patients without a prior history of 
cardiomyopathy are at very low risk of developing pregnancy-associated cardiomyopathy. 
Only 3 out of 804 such patients (0.3%) with no prior history of cardiomyopathy developed 
cardiomyopathy.
Our study is limited by its retrospective nature and the reliance of self-reporting of 
successful pregnancies and health problems, including cardiomyopathy, after completion of 
therapy. There was no prospective systematic ascertainment of pregnancy related 
cardiomyopathy and, despite best efforts, some inconsistency of echocardiographic 
screening over the years; therefore, our results are limited and based on last 
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echocardiographic information that was available and/or self-reporting of any 
cardiomyopathy the patient which was verified by obtained medical records. Although we 
initially identified pregnancy-associated cardiomyopathy in some survivors based on self-
report, potentially leading to under-reporting, records were obtained and reviewed to verify 
each case. We also cannot say with absolute certainty that patients that we reported with 
pregnancy-associated cardiomyopathy had no subclinical cardiomyopathy prior to 
pregnancy since last echocardiogram in those three cases were obtained 2 years prior to 
pregnancy. As in previous studies, we were unable to calculate true incidence rates and risk 
factors for pregnancy-associated cardiomyopathy because of low numbers of patients with 
the outcome and heterogeneity of the group examined. Given the retrospective nature of this 
study we were unable to determine if patients had scheduled screening echocardiograms 
during their pregnancies or had special follow-up with high-risk obstetrics because of their 
history of previous cardiotoxic treatment.
In conclusion, pregnancy-associated cardiomyopathy in childhood cancer survivors is rare 
(estimated incidence 3 in 1514 births or 1 in 500 births), but higher than the general 
population. Female childhood cancer survivors with a history of cardiotoxic therapies should 
be followed carefully during pregnancy, especially in patients with history of 
cardiomyopathy in the past. Referral to Maternal-Fetal-Medicine during pregnancy should 
be considered for those childhood cancer survivors with a history of anthracycline exposures 
and radiation therapy fields involving the heart, particularly if they have had documented 
previous or current subclinical or symptomatic cardiomyopathy. Counseling for 
contraception and preconception counseling is also important for this cohort as their 
pregnancy could unmask subclinical dysfunction.
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Figure. 
Flowchart showing the disposition of women with pregnancy-associated cardiomyopathy, as 
well as those with non-pregnancy associated cardiomyopathy.
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Table 2
Patient characteristics for non-pregnancy associated cardiomyopathy compared to pregnancy-associated 
cardiomyopathy
Non-pregnancy
associated CMP
(n=40)
(%) Pregnancy-associated
CMP
(n=3)
(%)
Radiation field involving the heart
  Yes 13 (32) 0
  No 27 (68) 3 (100)
Anthracycline cumulative dose (mg/m2)
  None 5 (12) 0 (0)
  ≥ 0 to 300 14 (35) 1 (33)
  ≥ 300 to 400 13 (33) 1 (33)
  ≥ 400 to 500 8 (20) 0 (0)
  ≥ 500 0 (0) 1 (33)
  Median dose for those exposed 331 mg/m2* 172 mg/m2*
  Range for those exposed 42–480 mg/m2 84–521 mg/m2
**
median anthracycline dose for non-pregnancy associated CMP versus pregnancy associated CMP, p=0.8; t-test;
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